What Really Mattered With Editas Medicine's Q1 Update
Editas Medicine (NASDAQ: EDIT) entered 2021 with tremendous momentum. That's definitely not the case anymore: Its shares are down more than 60% from their highs set in January.
The company announced its first-quarter results before the market opened on Wednesday. Investors pretty much yawned, with the biotech stock barely moving in early trading. Here are the highlights from Editas' Q1 update.
Image source: Getty Images.
Source Fool.com